> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-52/
- Published: 2021-11-21T12:00:00.000Z
- Updated: 2026-09-14T17:23:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138031

**Valeant Pharmaceuticals** and **EyeGate Pharmaceuticals** have entered into a licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the EyeGate II Delivery System and EGP-437 combination product candidate for treating post-operative pain and inflammation in ocular surgery patients. This partnership follows a 2015 agreement in which Valeant secured an exclusive worldwide license for its subsidiary to this product for uveitis. Valeant has maintained its right of last negotiation to license the product for other indications.

**Takeda Pharmaceutical Company** has completed its acquisition of **Ariad Pharmaceuticals** for $24.00 per share in cash. The transaction gives Takeda the global potential of brigatinib, an investigational ALK inhibitor for non-small cell lung cancer with the potential to achieve annual sales of over $1 billion.

**MedPlast** has signed a definitive agreement to acquire **Vention Medical**’s device manufacturing services business. The acquisition broadens MedPlast’s capabilities in assembly and packaging, enabling it to offer customers a comprehensive suite of services producing a wide range of medical products.